Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
Purpose
The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.
Condition
- Smooth Muscle Dysfunction Syndrome (SMDS)
Eligibility
- Eligible Ages
- Over 1 Year
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Individuals diagnosed with SMDS with confirmed ACTA2 mutation disrupting arginine 179 - Parental/guardian permission (informed consent) and, if appropriate, child assent.
Exclusion Criteria
- Individuals who have undergone surgery to replace aneurysmal or dissected ascending and root aortic tissue with a graft. - Additional medical conditions that impair the patient's ability to participate in the study. - Known allergy or sensitivity to niacin or nicotinamide riboside. - Prior consumption of niacin or nicotinamide riboside supplement within the prior eight weeks. - Failure to provide informed consent. - Concurrent participation in another intervention trial.
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Treatment |
|
Recruiting Locations
The University of Texas Health Science Center at Houston
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77030
More Details
- Status
- Recruiting
- Sponsor
- The University of Texas Health Science Center, Houston